SEARCH
Tynax ~ Patent Library

Patent for Sale:

ECG QT Interval Measurement Algorithm as per Electrophysiological Definition    

Negative and positive digital ECG images are superimposed to give best fit of common T wave baseline. First time of baseline intersection is end of T wave

Overview

The ECG QT interval prolongation is very important biomarker used to monitor cardiac safety of new pre-marketed compounds by the the pharmaceutical industry. The FDA/MHRA use this biomarker to determines if a new compound is "killed" because of potential cardiac risks. Billions of dollars are therefore at risk ensuring that the cardiac safety of new drug is accurately assessed. This patented computer algorithm accurately measures the real end of the T wave as per the elctrophysiological definition as opposed to other algorithms that are based on surrogate approximate measures of the end of the T wave. It achieves this by using and inverted image of the filtered original signal to find the first time of intersection between the common least squares fitted baselines of the inverted and original siganls. This enhances the accuracy of the QT interval biomarker as well as other biomarkers incorporating the end of the T wave (PeakT to T end). Errors secondary baseline shift are corrected by prefiltering and ECG signal variability from lead position, respiration and cardiac rotation are negated by converting the ECGG signal to the resultant vector in the time domain. The algorithm can measure intervals in real time applications and is ideal when used for assessing the effects of personalised medicines. The algorithm has been validated using the MIT clinical QT database in addition to computer simulation.

Primary Application of the Technology

Pharmaceutical companies.
ECG machine manufacturers -- particularly ECG devices used in the pharmaceutical safety sector

Pharmaceutical industry will use this more accurate cardiac safety biomarker as it will enhance the accuracy of identifying drugs with potentially fatal cardiac side effects. The biomarker reduces variability from noise secondary to baseline wander, respiration, cardiac motion, ECG lead malposition. The accuracy and reduced variability of measurement will reduce the cost of studies investigating the effects of drugs on QT interval because reduced standard measurement error will reduce number of subjects required for statistical power.

Pharmaceutical Personal medicine development will require accurate QT interval measurement. ECG machine companies will incorporate this patented algorithm.

The Problem Solved by the Technology

Computer algorithm measurement of the ECG end of T wave is prone to error because of its low amplitude low frequency. Baseline wander and noise secondary to respiratory movement, cardiac motion and mal lead positioning add to this measurement error. Currently used algorithms measure only surrogate approximate end of the T wave and do not address variability error problems of baseline, respiratory, cardiac and lead positioning. This algorithm measures the real end of the T wave as per electrophysiological definition and compensates for various sources of noise. Therefore the biomarker becomes more accurate. There is less standard error in its measurements. The Pharmaceutical industry FDA/MHRA can more accurately assess a new compounds cardiac safety and require less patients to provide proof of concept trial with high statistical power.

How the Technology Solves the Problem

Measures real end of T wave as per electrophysiological definition with less variability secondary to noise. Therefore more accurately assesses the cardiac safety of pharmaceutical compounds under investigation by FDA/MHRA prior to licensing.

Competitive Advantage

The competitive computer ECG algorithms rely on surrogate approximate measures of the end of the T wave - i.e. the tangent based methods determine the end of the T wave by the time point at which the maximum negative downslope on the T wave crosses some arbitrary baseline. The Tangent method is very prone to error of baseline shift and ignores the curvilinear tail end of the T wave. None of the currently used algorithms address problems of noise from baseline shift, respiratory cardiac motion, cardiac torsion or ECG vector lead misplacement.

The seller would like to be granted a license back.

Patent Summary

U.S. Patent Classes & Classifications Covered in this listing:

Class 600: Surgery

Subclass 509: Detecting heartbeat electric signal
Subclass 516: Variation in duration of segment of PQRST signal waveform (e.g., QRS complex, etc.) detected